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Abstract 
Background: The success of fat grafting in breast reconstruction depends on fat retention. The use of stem-cells-enriched fat graft is an 
alternative method for graft stability. 
Case report: A case of nipple-areola sparing mastectomy double stage reconstruction with the use of stem cells enhanced fat graft is 
reported. 
Conclusions: Fat grafting is growing as a new and promising tool in reconstruction following nipple and areola sparing mastectomies as 
a way to restore a sufficient and reliable subcutaneous space in the mastectomy flap. This combined with an anatomical gel implant 
offers an integrated system of achieving a natural shaped breast. 
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Introduction 
Through preservation of the areola–nipple (A/N) complex, the 
nipple–areola sparing mastectomy (NASM) serves to reduce the 
negative psychological impact on women without increasing the 
incidence of local relapse [1,2]. For many women, the A/N 
complex is a distinctive element of the breast and plays a key 
role defining their body image [3]. NASM is particularly indicated 
in mid- to small-breasted women with a neoplasia, which 
prohibits a conservative surgical approach due to a 
disadvantageous relationship between breast dimensions and 
tumour size [1]. 
Actually, NASM is contraindicated in cases of the following: 
1.  involvement of the skin above the neoplastic area; 
2.  evidence of neoplastic infiltration of the A/N complex 
(nipple retraction or haematic secretion); 
3.  distance between the neoplasia and the A/N complex 
of less than 10 mm; 
4. tumour  multiplicity; 
5.  relapse in case of previous breast tumour; 
6.  suspicious axillary adenopathy; 
7.  primary chemotherapeutic treatment. 
With NASM, the mammary gland is removed as well as the skin 
above the neoplasia when necessary. The incision can be made 
either inside the A/N complex (reverse omega), in the superior-
outer quadrant with a radial course, or in the infra-mammary 
fold. An immediate reconstruction is usually performed with a 
tissue expander, which is  replaced after six months by a 
definitive prosthesis with eventual symmetrization of the 
contralateral breast. 
 
Clinical case 
The patient is a 37-year-old woman with a positive genetic test 
for BRCA1 and a nodular neoformation in the superior-
outer/superior-inner quadrant of the right breast (x-ray 
mammograph: R5, breast ultrasound U5, AGB B5) Figure 1. 
She underwent bilateral NASMs with a right sentinel lymph 
node biopsy on 20 June 2007.  
Final histological examination documented infiltrating ductal 
carcinoma on the right side (NOS-G3 peritumoural 
haematic/lymphatic vascular invasion absent) with a minimum 
distance between the tumour and the nipple margin greater than 
10 mm. 
The sentinel lymph node biopsy was negative pT1c, psN0(i-). 
The biological characterization of the neoplasm was the 
following: ER neg-PGr neg-ki67 40%, c-erb-B2 neg, score 0. 
Histological examination of the tissue from the left breast 
demonstrated micro-fibroadenoma intracanalicolare (QSE) in 
the background of fibrocystic mastopathy. 
Immediately following the mastectomies, a bilateral 450 cc 
tissue expanders were positioned in a submuscular pocket 
Figure 2
The post-operative course was free of complication. In August 
2007, the patient underwent prophylactic bilateral 
oophorectomies. On 28 January 2008, the patient underwent 
the second stage of the breast reconstruction. A partial bilateral 
capsulotomy was followed by a careful injection of cell-
enhanced autologous fat into the subcutaneous areas. A total of 
85 cc of cell-enhanced fat graft was injected on the left breast 
and 90 cc on the right. The tissue was obtained through a 
syringe-based liposuction of 355 cc of adipose tissue from 
abdomen and external thighs, which was performed at the 
beginning of the case. The tissue was then processed using an 
automated device (Celution 800/CRS-Cytori) to produce a cell-
enhanced fat graft. 
The surgical procedure was completed with placement of 370-
cc bilateral silicone gel implants Figure 3
The patient was discharged on post-operative day 1 and had no 
complications in the post-operative course. The aesthetic result 
was evaluated during a ten month follow-up after the second 
procedure. The patient evaluated the result as excellent, the 
surgeon as good. Graft retention in the mastectomy flap was 
evaluated with MRI and ultrasound at three months Figure 4. 
The oncological follow-up was negative at 17 months for local 
relapses and systemic metastasis. 
 
Discussion 
Autologous fat grafting has been used to treat soft tissue 
defects for decades with varying degrees of success. Fat would 
be an ideal filler given the easy accessibility, lack of 
immunogenicity and low cost of adipose tissue, but survival of
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Figure 1: A 37-year-old patient before bilateral NASM (preoperative view) 
 
Figure 2: Post-operative view after bilateral NASM and immediate reconstruction with a bilateral 450 cc tissue expander
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Figure 3: Post-operative view after second stage of breast reconstruction with 370-cc bilateral silicone gel implants and injection of cell-
enhanced autologous fat (85 cc in the left side and 90 in the right side) 
 
 
Figure 4: Post-operative evaluation of graft retention by MRI at 3 months
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fat grafts has not been predictable [4,5]. Several studies have 
suggested that the addition of adipose-derived regenerative 
cells (ADRCs) to fat can lead to increased graft survival [6–9]. 
The mechanism of this effect is not fully understood but ADRCs 
are known to differentiate into replacement tissue, express 
growth factors, which enhance angiogenesis and modulate the 
inflammatory response favouring healing over scarring [10–13]. 
In this case report, a new technique is used to enrich a patient's 
fat with her own ADRCs to create a natural soft tissue filler. 
Cell-enhanced fat along with a silicone implant is used for 
breast reconstruction after NASM. The follow-up demonstrates 
that ADRC-enhanced fat grafting is a feasible option for breast 
reconstruction, which may lead to a more natural appearance 
than implant alone. 
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